Pfizer (NYSE:PFE) Stock Price Up 2.4% – Still a Buy?

Pfizer Inc. (NYSE:PFE) traded up 2.4% during mid-day trading on Tuesday. The company traded as high as $30.25 and last traded at $30.1370. Approximately 34,224,934 shares were traded during mid-day trading, a decline of 14% from the average session volume of 40,024,027 shares. The stock had previously closed at $29.44.

Key Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Healthcare-sector rotation supports PFE. Biotech and pharmaceutical stocks have shown relative strength during the technology and AI sell-off. Pfizer was identified as one of the sector’s standout performers, with investors attracted to its defensive revenue base, value profile and dividend income. Tech Stocks Took a Hit—These 2 Pharma Stocks Are Near New Highs
• Positive Sentiment: Pfizer’s turnaround narrative is gaining traction. Coverage highlighted the company’s recent oncology approvals and multibillion-dollar cancer collaboration as evidence that Pfizer is rebuilding growth beyond its pandemic-era products. Its latest reported quarter also exceeded analyst expectations for earnings and revenue, providing additional support for the stock. What Pfizer Bulls Got Right
• Neutral Sentiment: Pipeline updates remain under review. Pfizer completed its Phase 2 MAGNETISMM-3 study of elranatamab and announced an ongoing study examining etrasimod exposure in breastfeeding women. These updates may support long-term pipeline visibility, but the reports did not provide a clear, immediate earnings or regulatory catalyst. Pfizer’s Elranatamab Trial Update
• Neutral Sentiment: Analyst sentiment is cautious. Wells Fargo and RBC Capital maintained Hold ratings, indicating that investors may want more evidence that Pfizer’s oncology strategy can offset declining COVID-related revenue and other portfolio pressures. Pfizer Gets a Hold from Wells Fargo
• Negative Sentiment: Dividend sustainability remains a risk. Commentary questioned whether Pfizer’s substantial dividend is fully supported by cash flow, while the company’s dividend freeze could limit income-investor enthusiasm if financial performance weakens. Pfizer’s Dividend Freeze Raises a Bigger Question About Its Cash Flow

Analyst Ratings Changes

Several research firms have recently commented on PFE. JPMorgan Chase & Co. raised their price target on Pfizer from $28.00 to $30.00 and gave the stock a “neutral” rating in a research report on Friday, October 9th. Bank of America cut their price objective on Pfizer from $27.00 to $26.00 and set a “neutral” rating on the stock in a report on Friday, July 10th. Guggenheim reissued a “buy” rating on shares of Pfizer in a research note on Tuesday, October 13th. Wall Street Zen cut Pfizer from a “buy” rating to a “hold” rating in a report on Saturday, October 10th. Finally, HSBC lifted their target price on Pfizer from $28.00 to $30.00 and gave the company a “hold” rating in a research report on Thursday, September 10th. Five investment analysts have rated the stock with a Buy rating, fourteen have given a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $28.72.

Pfizer Price Performance

The company’s 50-day simple moving average is $28.05 and its 200 day simple moving average is $26.57. The company has a market cap of $171.77 billion, a PE ratio of 39.65, a PEG ratio of 2.01 and a beta of 0.32. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.96 and a current ratio of 1.27.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share for the quarter, topping analysts’ consensus estimates of $0.68 by $0.09. The business had revenue of $15.03 billion for the quarter, compared to analyst estimates of $14.40 billion. Pfizer had a return on equity of 19.63% and a net margin of 6.80%. The company’s revenue was up 2.6% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.78 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, sell-side analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, December 7th. Shareholders of record on Friday, November 6th will be issued a dividend of $0.43 per share. The ex-dividend date is Friday, November 6th. This represents a $1.72 annualized dividend and a yield of 5.7%. Pfizer’s dividend payout ratio is 226.32%.

Institutional Investors Weigh In On Pfizer

Hedge funds have recently bought and sold shares of the stock. BlackRock Inc. grew its stake in Pfizer by 6.3% in the 2nd quarter. BlackRock Inc. now owns 529,670,433 shares of the biopharmaceutical company’s stock valued at $12,754,464,000 after acquiring an additional 31,412,883 shares during the last quarter. State Street Corp increased its stake in shares of Pfizer by 1.8% during the 2nd quarter. State Street Corp now owns 307,090,897 shares of the biopharmaceutical company’s stock worth $7,394,749,000 after purchasing an additional 5,501,032 shares in the last quarter. Bank of New York Mellon Corp raised its position in shares of Pfizer by 7.4% during the 2nd quarter. Bank of New York Mellon Corp now owns 57,879,546 shares of the biopharmaceutical company’s stock worth $1,393,739,000 after purchasing an additional 3,999,646 shares during the last quarter. Bank of America Corp DE acquired a new position in shares of Pfizer during the 2nd quarter worth approximately $1,049,602,000. Finally, Dimensional Fund Advisors LP lifted its stake in Pfizer by 0.8% in the 1st quarter. Dimensional Fund Advisors LP now owns 36,422,799 shares of the biopharmaceutical company’s stock valued at $1,022,606,000 after buying an additional 293,029 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Company Profile

Pfizer Inc is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its research activities span areas including oncology, internal medicine, inflammation and immunology, hospital care, infectious diseases and rare diseases.

The company’s portfolio includes medicines such as Eliquis, Ibrance, Prevnar and Vyndaqel, as well as vaccines including Comirnaty, Abrysvo and Prevnar. Pfizer also develops treatments through internal research, licensing agreements and collaborations with other pharmaceutical and biotechnology companies.

Founded in Brooklyn, New York, in 1849 by Charles Pfizer and Charles Erhart, Pfizer has grown into an international healthcare company serving patients and healthcare providers in markets around the world.